Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

The NFκB/COX2 Pathway Mediates the Inhibition of CAR-T Cell Proliferation and Function By Bone Marrow Stroma

Roberto Savoldelli, Alice Pievani, Sarah Tettamanti, Chiara Giacomini, Anna Kozlowska, Marta Serafini, Francesco Dazzi

Blood (2024) 144 (Supplement 1): 3426.

https://doi.org/10.1182/blood-2024-209939

Published: 2024

Journal Articles

Cord Blood-Derived Carcik Cells As Off-the-Shelf Non-Viral Cell Therapy for Hematological Malignancies

Blood (2024) 144 (Supplement 1): 4849.

https://doi.org/10.1182/blood-2024-211472

Published: 2024

Journal Articles

Manufacturing, Characterization and Anti-Tumor Activity of Allogeneic CD19-CAR Cytokine-Induced Killer (CIK) Cells Engineered with Non-Viral Sleeping Beauty Transposon System and Armored with IL-18

Laura Contreras-Ruiz, Barcley Pace, Dora E Kohnke, Lindsey Viruet, Melissa Adams, John F Krisko, Noah Leesnitzer, Marissa Velie, Sarah Tettamanti, Ilaria Pisani, Giusi Melita, Andrea Biondi, Alessandro Rambaldi, Irina Y Tcherepanova, Renier Brentjens, Charles A Nicolette

Blood (2023) 142 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2023-181005

Published: 2023

Journal Articles

Bone Marrow Stroma Impairs CAR-T Cell Proliferation and Function: Mechanistic Insights

Francesco Dazzi, Roberto Savoldelli, Alice Pievani, Sarah Tettamanti, Chiara Giacomini, Anna Kozlowska, Marta Serafini

Blood (2023) 142 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2023-178675

Published: 2023

Journal Articles

Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden

Marta Biondi, Sarah Tettamanti, Stefania Galimberti, Beatrice Cerina, Chiara Tomasoni, Rocco Piazza, Samantha Donsante, Simone Bido, Vincenzo Maria Perriello, Vania Broccoli, Andrea Doni, Francesco Dazzi, Alberto Mantovani, Gianpietro Dotti, Andrea Biondi, Alice Pievani, Marta Serafini

Blood (2023) 141 (21): 2587–2598.

https://doi.org/10.1182/blood.2022018330

Published: 2023

Includes: Supplemental data

Journal Articles

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Blood (2022) 140 (Supplement 1): 4568–4569.

https://doi.org/10.1182/blood-2022-165448

Published: 2022

Journal Articles

Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 10237–10238.

https://doi.org/10.1182/blood-2022-166555

Published: 2022

Journal Articles

Overexpression of CXCR4 Enhances the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia

Marta Biondi, Stefania Galimberti, Beatrice Cerina, Chiara Tomasoni, Gianpietro Dotti, Sarah Tettamanti, Andrea Biondi, Alice Pievani, Marta Serafini

Blood (2022) 140 (Supplement 1): 4500–4501.

https://doi.org/10.1182/blood-2022-163130

Published: 2022

Journal Articles

Carcik-CD19 Cells Expand In Vivo Toward a CD8 + Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Blood (2022) 140 (Supplement 1): 10339–10340.

https://doi.org/10.1182/blood-2022-166788

Published: 2022

Journal Articles

CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-CIK Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia

Vincenzo Maria Perriello, Maria Caterina Rotiroti, Ilaria Pisani, Gaia Alberti, Giulia Pianigiani, Roberta Rossi, Valerio Ciaurro, Marta Serafini, Maria Paola Martelli, Brunangelo Falini, Andrea Biondi, Sarah Tettamanti

Blood (2021) 138 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2021-150487

Published: 2021

Journal Articles

Combining the Expression of CD33.CAR and CXCR4 to Increase CAR-CIK Cell Homing to Bone Marrow Niche and Leukemic Stem Cell Eradication in Acute Myeloid Leukemia

Marta Biondi, Beatrice Cerina, Chiara Tomasoni, Gianpietro Dotti, Sarah Tettamanti, Andrea Biondi, Alice Pievani, Marta Serafini

Blood (2021) 138 (Supplement 1): 2791.

https://doi.org/10.1182/blood-2021-152394

Published: 2021

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Blood (2021) 138 (Supplement 1): 472.

https://doi.org/10.1182/blood-2021-148703

Published: 2021

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141236

Published: 2020

Journal Articles

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Maria Caterina Rotiroti, PhD, Chiara Buracchi, PhD, Silvia Arcangeli, PhD, Chiara F Magnani, PhD, Claudia Cappuzzello, PhD, Zsuzsanna Izsvak, PhD, Stefania Galimberti, PhD, Maria Grazia Valsecchi, PhD, Giuseppe Dastoli, MD, Marta Serafini, PhD, Ettore Biagi, MD, Andrea Biondi, MD, Sarah Tettamanti, PhD

Blood (2019) 134 (Supplement_1): 2665.

https://doi.org/10.1182/blood-2019-130399

Published: 2019

Journal Articles

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2019) 134 (Supplement_1): 200.

https://doi.org/10.1182/blood-2019-125894

Published: 2019

Journal Articles

Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)

Maria Caterina Rotiroti, MSc, Silvia Arcangeli, PhD, Chiara Buracchi, PhD, Chiara Francesca Magnani, PhD, Claudia Cappuzzello, PhD, Ettore Biagi, MD, Sarah Tettamanti, PhD, Andrea Biondi, MD

Blood (2018) 132 (Supplement 1): 2201.

https://doi.org/10.1182/blood-2018-99-114572

Published: 2018

Journal Articles

Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications

Blood (2018) 132 (Supplement 1): 196.

https://doi.org/10.1182/blood-2018-196

Published: 2018

Journal Articles

Sleeping Beauty Modified CAR+ Lymphocytes Engraft and Exhibit Anti-Tumor Activity in Patient-Derived Xenograft Models of Acute Lymphoblastic Leukemia

Chiara F. Magnani, PhD, Claudia Mezzanotte, Claudia Cappuzzello, PhD, Fabrizio Benedicenti, Michela Bardini, PhD, Sarah Tettamanti, PhD, Grazia Fazio, PhD, Gianni Cazzaniga, PhD, Laurence J.N. Cooper, MD PhD, Eugenio Montini, PhD, Andrea Biondi, MD, Ettore Biagi, MD PhD

Blood (2016) 128 (22): 4022.

https://doi.org/10.1182/blood.V128.22.4022.4022

Published: 2016

Journal Articles

Balance of Anti-CD123 Chimeric Antigen Receptor (CAR) Binding Affinity and Density for the Treatment of Acute Myeloid Leukemia

Silvia Arcangeli, PhD, Marco Bardelli, PhD, Maria Caterina Rotiroti, Luca Simonelli, PhD, Chiara F. Magnani, PhD, Luca Varani, PhD, Andrea Biondi, MD, Ettore Biagi, MD, Sarah Tettamanti, PhD

Blood (2016) 128 (22): 2163.

https://doi.org/10.1182/blood.V128.22.2163.2163

Published: 2016

Journal Articles

Unraveling the Efficacy and Safety Profiles of Anti-CD123 Chimeric Antigen Receptors (CARs) in a Model of Acute Myeloid Leukemia Immunotherapy By Investigating CAR Binding Affinity and Density Variables

Silvia Arcangeli, Marco Bardelli, Sarah Tettamanti, Maria Caterina Rotiroti, Luca Simonelli, Chiara F Magnani, Luca Varani, Andrea Biondi, Prof, MD, Ettore Biagi, MD

Blood (2015) 126 (23): 1359.

https://doi.org/10.1182/blood.V126.23.1359.1359

Published: 2015

NARROW

The NFκB/COX2 Pathway Mediates the Inhibition of CAR-T Cell Proliferation and Function By Bone Marrow Stroma

Cord Blood-Derived Carcik Cells As Off-the-Shelf Non-Viral Cell Therapy for Hematological Malignancies

Manufacturing, Characterization and Anti-Tumor Activity of Allogeneic CD19-CAR Cytokine-Induced Killer (CIK) Cells Engineered with Non-Viral Sleeping Beauty Transposon System and Armored with IL-18

Bone Marrow Stroma Impairs CAR-T Cell Proliferation and Function: Mechanistic Insights

Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

Overexpression of CXCR4 Enhances the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia

Carcik-CD19 Cells Expand In Vivo Toward a CD8 + Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-CIK Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia

Combining the Expression of CD33.CAR and CXCR4 to Increase CAR-CIK Cell Homing to Bone Marrow Niche and Leukemic Stem Cell Eradication in Acute Myeloid Leukemia

Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)

Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications

Sleeping Beauty Modified CAR+ Lymphocytes Engraft and Exhibit Anti-Tumor Activity in Patient-Derived Xenograft Models of Acute Lymphoblastic Leukemia

Balance of Anti-CD123 Chimeric Antigen Receptor (CAR) Binding Affinity and Density for the Treatment of Acute Myeloid Leukemia

Unraveling the Efficacy and Safety Profiles of Anti-CD123 Chimeric Antigen Receptors (CARs) in a Model of Acute Myeloid Leukemia Immunotherapy By Investigating CAR Binding Affinity and Density Variables

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only